Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 7/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092134 | 0.91 | TNFRSF1A (0.52) | TNFRSF1AERN1HDAC6HDAC2MEN1 | |
| SCHEMBL6091940 | 0.80 | TNFRSF1A (0.52) | TNFRSF1AHDAC2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6091816 | 0.78 | TNFRSF1A (0.55) | TNFRSF1AERN1HDAC6ACLYHDAC2 | |
| SCHEMBL731486 | 0.77 | APP (0.65) | TNFRSF1AERN1ACLYHDAC2APP | |
| SCHEMBL6091620 | 0.76 | TNFRSF1A (0.52) | TNFRSF1AHDAC6ACLYMEN1NPC1 | |
| SCHEMBL6091606 | 0.76 | PDGFRB (0.56) | LTB4RMEN1NPC1RAB9AKMT2A | |
| SCHEMBL6091799 | 0.74 | CHEK2 (0.43) | ERN1LTB4RHDAC2NPC1L3MBTL1 | |
| SCHEMBL10436312 | 0.73 | TNFRSF1A (0.61) | TNFRSF1AERN1NPC1RAB9AS1PR1 | |
| SCHEMBL6093061 | 0.73 | MKNK1 (0.56) | LTB4RACLY | |
| SCHEMBL6091721 | 0.72 | TNFRSF1A (0.54) | TNFRSF1AMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ATHEROGENICS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063828-A1 | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof | ABCB11, CEL, CYP46A1 | TNFRSF1A 4880/4885ERN1 2367/4885HDAC6 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.